#SARS-CoV-2

NIH-funded study suggests need to boost CD8+ T cell response after infection.

With further development, the gel could provide additional protection against COVID-19 and other respiratory illnesses.

Experts stress the need for targeted efforts to increase vaccine uptake among cancer patients with lower vaccination rates.

Several mechanisms may play a role, including persistent virus and ongoing immune dysregulation.

Researchers encourage additional studies to determine why Black and Latino people experience long COVID symptoms more than white people.

The results suggest that preventing viral infections might reduce the risk for diseases like Alzheimers and multiple sclerosis.

The condition may be caused by hidden viral reservoirs that remain in the body after initial infection.

Increased protection against hospitalization or death was seen regardless of age or history of previous boosters.

While regular boosters may help keep vulnerable people out of the hospital, annual boosters might not be necessary for everyone.

COVID is associated with serious illness in mothers and newborns. Findings reinforce need for targeted interventions, including vaccination.

Before they get COVID, people over 65 should have a plan for accessing antiviral treatment.

Berks County, Pennsylvania, is the first community to join a partnership with local public health departments.

Older people, immunocompromised people and those with underlying health conditions can benefit most from additional shots.

The antiviral treatment reduced the risk of hospitalization or death from SARS-CoV-2 Omicron variants in older adults by 44%.

NIH-supported study finds no serious complications following rare immune condition.

Investigational drug works differently than antibody drugs which are losing effectiveness against the SARS-CoV-2 virus.